WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Forecast Score
Market Cap
Price
Price Target
Upside/Downside
Top Analysts Upside/Downside
Consensus
Top Analysts Consensus
Analysts
Top Analysts
Fore. Revenue Growth
Fore. Earnings Growth
Forecast ROE
Forecast ROA
MRVI
MARAVAI LIFESCIENCES HOLDINGS INC
$2.85B$11.32$11.400.71%Strong Buy54.89%N/AN/AN/A
SNTI
SENTI BIOSCIENCES INC
$17.48M$0.38N/AN/AN/AN/A198.04%N/AN/AN/A
SNGX
SOLIGENIX INC
$6.21M$0.39N/AN/AN/AN/A14.51%N/AN/AN/A
CGEN
COMPUGEN LTD
$186.56M$2.11$4.50113.27%Strong Buy2-2.46%N/AN/AN/A
INMB
INMUNE BIO INC
$214.64M$10.85N/AN/AN/AN/AN/AN/AN/AN/A
GNLX
GENELUX CORP
$98.54M$3.65$31.00749.32%Buy22,630.96%N/AN/AN/A
CYTK
CYTOKINETICS INC
$6.24B$59.53$95.0059.58%Buy10318.07%N/AN/AN/A
BNTC
BENITEC BIOPHARMA INC
$88.90M$9.49$16.0068.60%Buy12,915.72%N/AN/AN/A
LGVN
LONGEVERON INC
$8.13M$1.28$12.00837.50%Buy1132.36%N/AN/AN/A
CELU
CELULARITY INC
$58.13M$3.00N/AN/AN/AN/A73.55%N/AN/AN/A
GYRE
GYRE THERAPEUTICS INC
$1.22B$14.24N/AN/AN/AN/A0.83%N/AN/AN/A
KALV
KALVISTA PHARMACEUTICALS INC
$502.88M$11.92$27.50130.70%Buy2N/AN/AN/AN/A
CARA
CARA THERAPEUTICS INC
$41.01M$0.75$6.20726.67%Strong Buy3-25.18%N/AN/AN/A
CMMB
CHEMOMAB THERAPEUTICS LTD
$11.96M$0.84$5.67573.84%Strong Buy3N/AN/A-10,239.47%-7,579.68%
KOD
KODIAK SCIENCES INC
$173.37M$3.30$3.331.00%Strong Sell3N/AN/AN/AN/A
PRTG
PORTAGE BIOTECH INC
$5.06M$0.26$6.002,243.75%Buy1N/AN/AN/AN/A
RARE
ULTRAGENYX PHARMACEUTICAL INC
$3.48B$41.87$80.1191.33%Strong Buy923.15%N/AN/AN/A
NEXI
NEXIMMUNE INC
$4.57M$3.34N/AN/AN/AN/AN/AN/AN/AN/A
PHVS
PHARVARIS NV
$1.10B$20.35$31.5054.79%Buy4N/AN/AN/AN/A
LIXT
LIXTE BIOTECHNOLOGY HOLDINGS INC
$5.53M$2.46N/AN/AN/AN/AN/AN/AN/AN/A
GOVX
GEOVAX LABS INC
$3.92M$1.70N/AN/AN/AN/AN/AN/AN/AN/A
SANA
SANA BIOTECHNOLOGY INC
$1.93B$8.73$13.5054.64%Buy2N/AN/AN/AN/A
XTLB
XTL BIOPHARMACEUTICALS LTD
$14.67M$2.69N/AN/AN/AN/AN/AN/AN/AN/A
REVB
REVELATION BIOSCIENCES INC
$3.30M$2.02N/AN/AN/AN/AN/AN/AN/AN/A
KYTX
KYVERNA THERAPEUTICS INC
$664.84M$15.42$39.50156.16%Strong Buy2N/AN/AN/AN/A
VIRX
VIRACTA THERAPEUTICS INC
$31.69M$0.81$8.50953.28%Buy2N/AN/AN/AN/A
LXEO
LEXEO THERAPEUTICS INC
$456.29M$13.85$21.2053.07%Strong Buy5N/AN/AN/AN/A
ESLA
ESTRELLA IMMUNOPHARMA INC
$36.92M$1.02N/AN/AN/AN/AN/AN/AN/AN/A
ENSC
ENSYSCE BIOSCIENCES INC
$4.73M$0.62N/AN/AN/AN/AN/AN/AN/AN/A
NAMS
NEWAMSTERDAM PHARMA CO NV
$1.81B$20.09$33.2565.51%Strong Buy4N/AN/AN/AN/A
BCDA
BIOCARDIA INC
$10.70M$0.39N/AN/AN/AN/A118.27%N/AN/AN/A
EDSA
EDESA BIOTECH INC
$14.63M$4.55$21.00361.54%Buy1N/AN/AN/AN/A
DARE
DARE BIOSCIENCE INC
$49.03M$0.49$4.50827.84%Strong Buy2238.23%N/AN/AN/A
NMRA
NEUMORA THERAPEUTICS INC
$1.54B$9.67$26.50174.04%Strong Buy2N/AN/AN/AN/A
TPST
TEMPEST THERAPEUTICS INC
$70.65M$3.18$25.00686.16%Strong Buy3N/AN/AN/AN/A
NVCT
NUVECTIS PHARMA INC
$112.89M$6.15$21.00241.46%Buy1N/AN/AN/AN/A
CRIS
CURIS INC
$69.55M$11.80$26.00120.34%Strong Buy22.13%N/AN/AN/A
PROK
PROKIDNEY CORP
$939.54M$4.06$2.50-38.35%Hold2N/AN/AN/AN/A
TCBP
TC BIOPHARM (HOLDINGS) PLC
$5.59M$1.13N/AN/AN/AN/AN/AN/AN/AN/A
VERU
VERU INC
$193.23M$1.32$4.00203.03%Strong Buy4-10.92%N/AN/AN/A
MTNB
MATINAS BIOPHARMA HOLDINGS INC
$42.64M$0.17N/AN/AN/AN/AN/AN/AN/AN/A
AVBP
ARRIVENT BIOPHARMA INC
$673.22M$20.10$29.2545.52%Strong Buy4N/AN/AN/AN/A
APLM
APOLLOMICS INC
$29.71M$0.33$4.251,180.12%Strong Buy2N/AN/AN/AN/A
ANL
ADLAI NORTYE LTD
$488.44M$13.25N/AN/AN/AN/AN/AN/AN/AN/A
MURA
MURAL ONCOLOGY PLC
$63.63M$3.76$13.00245.74%Strong Buy1N/AN/AN/AN/A
IMNN
IMUNON INC
$13.16M$1.40$12.00757.14%Buy1N/AN/AN/AN/A
CRGX
CARGO THERAPEUTICS INC
$804.06M$20.42$29.0042.02%Strong Buy3N/AN/AN/AN/A
PHIO
PHIO PHARMACEUTICALS CORP
$3.61M$0.79$4.00408.26%Buy1N/AN/AN/AN/A
CLRB
CELLECTAR BIOSCIENCES INC
$118.30M$3.30$20.00506.06%Strong Buy2N/AN/AN/AN/A
CKPT
CHECKPOINT THERAPEUTICS INC
$69.28M$1.88$19.00910.64%Strong Buy21,651.00%N/AN/AN/A
VANI
VIVANI MEDICAL INC
$109.68M$2.00N/AN/AN/AN/AN/AN/AN/AN/A
ANRO
ALTO NEUROSCIENCE INC
$335.24M$12.47$32.33159.29%Strong Buy3N/AN/AN/AN/A
SLRX
SALARIUS PHARMACEUTICALS INC
$2.36M$0.49N/AN/AN/AN/AN/AN/AN/AN/A
VCNX
VACCINEX INC
$8.78M$5.54N/AN/AN/AN/AN/AN/AN/AN/A
CGON
CG ONCOLOGY INC
$2.00B$29.98$63.75112.64%Strong Buy4N/AN/AN/AN/A
CERE
CEREVEL THERAPEUTICS HOLDINGS INC
$7.67B$42.10$45.006.89%Hold7N/AN/AN/AN/A
CYBN
CYBIN INC
$143.93M$0.35$5.001,328.57%Buy1N/AN/AN/AN/A
CHRO
CHROMOCELL THERAPEUTICS CORP
$10.09M$1.75N/AN/AN/AN/AN/AN/AN/AN/A
SCPX
SCORPIUS HOLDINGS INC
$3.71M$0.10N/AN/AN/AN/A136.49%N/AN/AN/A
XLO
XILIO THERAPEUTICS INC
$42.08M$1.14N/AN/AN/AN/AN/AN/AN/AN/A
ASMB
ASSEMBLY BIOSCIENCES INC
$80.11M$14.53N/AN/AN/AN/AN/AN/AN/AN/A
INBX
INHIBRX INC
$1.82B$34.70$27.00-22.19%Buy1N/AN/AN/AN/A
CNTX
CONTEXT THERAPEUTICS INC
$150.00M$2.00$6.50225.00%Strong Buy3N/AN/AN/AN/A
AKBA
AKEBIA THERAPEUTICS INC
$241.04M$1.15$5.00334.78%Strong Buy24.80%N/AN/AN/A
ICCC
IMMUCELL CORP
$37.58M$4.81N/AN/AN/AN/AN/AN/AN/AN/A
PTCT
PTC THERAPEUTICS INC
$2.54B$33.10$33.601.53%Buy5-4.62%N/AN/AN/A
ADXN
ADDEX THERAPEUTICS LTD
$8.80M$8.79N/AN/AN/AN/AN/AN/AN/AN/A
MBIO
MUSTANG BIO INC
$3.90M$0.31$2.00541.03%Buy1N/AN/AN/AN/A
KZIA
KAZIA THERAPEUTICS LTD
$7.43M$0.28N/AN/AN/AN/AN/AN/AN/AN/A
SMMT
SUMMIT THERAPEUTICS INC
$3.12B$4.44$7.5068.92%Strong Buy2N/AN/AN/AN/A
MRSN
MERSANA THERAPEUTICS INC
$334.05M$2.73$6.33131.98%Buy6-7.31%N/AN/AN/A
OMER
OMEROS CORP
$199.91M$3.45N/AN/AN/AN/AN/AN/A-63.36%10.33%
JAGX
JAGUAR HEALTH INC
$76.53M$0.26N/AN/AN/AN/AN/AN/AN/AN/A
RNAZ
TRANSCODE THERAPEUTICS INC
$7.62M$1.15$3.00160.87%Buy1N/AN/AN/AN/A
IKT
INHIBIKASE THERAPEUTICS INC
$11.20M$1.73$27.001,460.69%Buy1N/AN/AN/AN/A
AVTX
AVALO THERAPEUTICS INC
$9.92M$9.59$35.00264.96%Buy1-12.64%N/AN/AN/A
EVAX
EVAXION BIOTECH A
$14.10M$3.72$11.00195.70%Strong Buy2817.27%N/AN/AN/A
TRVN
TREVENA INC
$7.43M$0.41$5.001,134.57%Buy1143.05%N/AN/AN/A
CSBR
CHAMPIONS ONCOLOGY INC
$63.89M$4.70N/AN/AN/AN/A27.17%N/AN/AN/A
EYEN
EYENOVIA INC
$40.40M$0.75$12.001,500.00%Buy11,450.94%N/AN/AN/A
CTCX
CARMELL CORP
$42.65M$2.05N/AN/AN/AN/AN/AN/AN/AN/A
BIVI
BIOVIE INC
$30.02M$0.49$5.00916.26%Buy1N/AN/AN/AN/A
PSTV
PLUS THERAPEUTICS INC
$12.78M$2.24N/AN/AN/AN/A6.06%N/AN/AN/A
INTS
INTENSITY THERAPEUTICS INC
$67.05M$4.89$12.00145.40%Buy1N/AN/AN/AN/A
GUTS
FRACTYL HEALTH INC
$338.15M$7.06$18.00154.96%Strong Buy1N/AN/AN/AN/A
SLS
SELLAS LIFE SCIENCES GROUP INC
$84.32M$1.46$3.00105.48%Strong Buy1N/AN/AN/AN/A
FNCH
FINCH THERAPEUTICS GROUP INC
$3.12M$1.94N/AN/AN/AN/AN/AN/AN/AN/A
GANX
GAIN THERAPEUTICS INC
$47.48M$2.63$8.00204.18%Strong Buy3N/AN/AN/AN/A
ATXI
AVENUE THERAPEUTICS INC
$3.51M$3.73$56.251,408.04%Strong Buy1N/AN/AN/AN/A
MGX
METAGENOMI INC
$262.25M$7.00$17.83154.76%Strong Buy6N/AN/AN/AN/A
MREO
MEREO BIOPHARMA GROUP PLC
$448.87M$3.20$6.50103.13%Strong Buy2N/AN/AN/AN/A
COEP
COEPTIS THERAPEUTICS HOLDINGS INC
$12.99M$0.35N/AN/AN/AN/AN/AN/AN/AN/A
MLEC
MOOLEC SCIENCE SA
$45.08M$1.20$6.00400.00%Strong Buy1102.36%N/AN/AN/A
EPRX
EUPRAXIA PHARMACEUTICALS INC
$104.73M$2.94N/AN/AN/AN/AN/AN/AN/AN/A
NRXS
NEURAXIS INC
$20.05M$3.04N/AN/AN/AN/AN/AN/AN/AN/A
CING
CINGULATE INC
$4.85M$0.80$8.00897.51%Buy1N/AN/AN/AN/A
ANEB
ANEBULO PHARMACEUTICALS INC
$59.65M$2.30N/AN/AN/AN/AN/AN/AN/AN/A
PHGE
BIOMX INC
$18.72M$0.34$2.00489.97%Buy1N/AN/AN/AN/A
BCAB
BIOATLA INC
$136.17M$2.83$9.50235.69%Buy2N/AN/AN/AN/A
TELO
TELOMIR PHARMACEUTICALS INC
$182.99M$6.18N/AN/AN/AN/AN/AN/AN/AN/A

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in May 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Corcept Therapeutics (NASDAQ:CORT)


Corcept Therapeutics (NASDAQ:CORT) is the top biotech stock with a Zen Score of 67, which is 45 points higher than the biotech industry average of 22. It passed 22 out of 33 due diligence checks and has strong fundamentals. Corcept Therapeutics has seen its stock return 14.93% over the past year, overperforming other biotech stocks by 35 percentage points.

Corcept Therapeutics has an average 1 year price target of $40.67, an upside of 44.77% from Corcept Therapeutics's current stock price of $28.09.

Corcept Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Corcept Therapeutics, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the second best biotech stock with a Zen Score of 64, which is 42 points higher than the biotech industry average of 22. It passed 20 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -11.54% over the past year, overperforming other biotech stocks by 8 percentage points.

Incyte has an average 1 year price target of $74.92, an upside of 31.21% from Incyte's current stock price of $57.10.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 30.77% have issued a Strong Buy rating, 23.08% have issued a Buy, 46.15% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the third best biotech stock with a Zen Score of 62, which is 40 points higher than the biotech industry average of 22. It passed 21 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -18.29% over the past year, overperforming other biotech stocks by 1 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $39.80, an upside of 37.1% from Harmony Biosciences Holdings's current stock price of $29.03.

Harmony Biosciences Holdings stock has a consensus Hold recommendation according to Wall Street analysts. Of the 5 analysts covering Harmony Biosciences Holdings, 40% have issued a Strong Buy rating, 20% have issued a Buy, 0% have issued a hold, while 20% have issued a Sell rating, and 20% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 2 biotech stocks that have issued dividends in the past year, the 2 biotech stocks with the highest dividend yields are:

1. Novo Nordisk A S (NYSE:NVO)


Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.04%, which is the same as the biotech industry average of 0.72%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 47.8% indicates that its dividend yield is sustainable for the long-term.

2. Bio Techne (NASDAQ:TECH)


Bio Techne (NASDAQ:TECH) has an annual dividend yield of 0.38%, which is the same as the biotech industry average of 0.72%. Bio Techne's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Bio Techne's dividend has shown consistent growth over the last 10 years.

Bio Techne's dividend payout ratio of 25.2% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -0.7% in the last day, and up 1.84% over the last week. Jaguar Health was the among the top losers in the biotechnology industry, dropping -9.76% yesterday.

Jaguar Health shares are trading lower after the company announced a 1-for-60 reverse stock split.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 72 points higher than the biotech industry average of 14. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -11.54% in the past year. It has overperformed other stocks in the biotech industry by 8 percentage points.

2. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 86, which is 72 points higher than the biotech industry average of 14. It passed 6 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -17.24% in the past year. It has overperformed other stocks in the biotech industry by 2 percentage points.

3. Corcept Therapeutics (NASDAQ:CORT)


Corcept Therapeutics (NASDAQ:CORT) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Corcept Therapeutics has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Corcept Therapeutics's stock has gained 14.93% in the past year. It has overperformed other stocks in the biotech industry by 35 percentage points.

Are biotech stocks a good buy now?

51.92% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 77.73% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 8.47x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.